Evidence map›Paper›PMID 28797090›Full record

ArticlePloS one2017

Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Alexis Courbet, Nicole Bec, Caroline Constant, Christian Larroque, Martine Pugniere, Safia El Messaoudi, Zahraa Zghaib, Sonia Khier, Carine Deleuze-Masquefa, Florence Gattacceca

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Dissecting the role of imiquimod and isostearic acid in Aldara-induced psoriasis mouse model.JID innovations : skin science from molecules to population health · 2026
    Article
  3. Article
  4. Review
  5. [1,2,4]triazolo[4,3-Molecules (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Alexis CourbetUniversity of Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0003-0539-7011
Nicole BecUniversity of Montpellier, Montpellier, France.
Caroline ConstantIRCM, Institut de Recherche en Cancérologie de Montpellier INSERM U1194, Montpellier, France.
Christian LarroqueUniversity of Montpellier, Montpellier, France.
Martine PugniereUniversity of Montpellier, Montpellier, France.
Safia El MessaoudiUniversity of Montpellier, Montpellier, France.
Zahraa ZghaibIBMM, Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, Montpellier, France.
Sonia KhierUniversity of Montpellier, Montpellier, France.
Carine Deleuze-MasquefaIBMM, Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, Montpellier, France.
Florence GattaccecaUniversity of Montpellier, Montpellier, France.
Inserm · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Displaying a strong antiproliferative activity on a wide variety of cancer cells, EAPB0203 and EAPB0503 belong to the imidazo[1,2-a]quinoxalines family of imiquimod structural analogues. EAPB0503 has been shown to inhibit tubulin polymerization. The aim of the present study is to characterize the interaction of EAPB0203 and EAPB0503 with tubulin. We combine experimental approaches at the cellular and the molecular level both in vitro and in silico in order to evaluate the interaction of EAPB0203 and EAPB0503 with tubulin. We examine the influence of EAPB0203 and EAPB0503 on the cell cycle and fate, explore the binding interaction with purified tubulin, and use a computational molecular docking model to determine the binding modes to the microtubule. We then use a drug combination study with other anti-microtubule agents to compare the binding site of EAPB0203 and EAPB0503 to known potent tubulin inhibitors. We demonstrate that EAPB0203 and EAPB0503 are capable of blocking human melanoma cells in G2 and M phases and inducing cell death and apoptosis. Second, we show that EAPB0203 and EAPB0503, but also unexpectedly imiquimod, bind directly to purified tubulin and inhibit tubulin polymerization. As suggested by molecular docking and binding competition studies, we identify the colchicine binding site on β-tubulin as the interaction pocket. Furthermore, we find that EAPB0203, EAPB0503 and imiquimod display antagonistic cytotoxic effect when combined with colchicine, and disrupt tubulin network in human melanoma cells. We conclude that EAPB0203, EAPB0503, as well as imiquimod, interact with tubulin through the colchicine binding site, and that the cytotoxic activity of EAPB0203, EAPB0503 and imiquimod is correlated to their tubulin inhibiting effect. These compounds appear as interesting anticancer drug candidates as suggested by their activity and mechanism of action, and deserve further investigation for their use in the clinic.

Indexed as

Antineoplastic AgentsApoptosisBinding SitesCell CycleCell DeathCell Line, TumorCell ProliferationColchicineComputer SimulationHumansModels, MolecularMolecular Docking SimulationProtein BindingQuinoxalinesTubulinTubulin ModulatorsAntineoplastic AgentsColchicineEAPB0203EAPB0503QuinoxalinesTubulinTubulin Modulators

Identifiers

PMID28797090
PMCPMC5552358
OpenAlexW2743654770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.